Point of Care Testing Market : Current Scenario and Forecast (2019-2025): Emphasis on Product (Blood Glucose Monitoring Test, Pregnancy & Fertility Testing, Infectious Disease Testing, Cardiac Markers, Anticoagulant Management, Others), Prescription (Near the Patient Testing (NPT), Over the Counter (OCT) /Patient Self-Testing (PST)), End-User (Hospitals, Clinics & Laboratory, Home Setting, Other Health Facilities) and Regions/countries
- UNI4065898
- 298 Pages
- December 2019
- Healthcare
Increasing Prevalence of Chronic Diseases paired with Rising Geriatric (Elderly) Population is the major factor driving the adoption of POCT service. Costly chronic care needs are growing and exerting considerable demand for health systems. Chronic diseases are among the most prevalent and costly health conditions in the United States. Nearly half (approximately 45%, or 133 Million) of all Americans suffer from at least one chronic disease, and the number is growing. Chronic diseases including, cancer, diabetes, hypertension, stroke, heart disease, respiratory diseases, arthritis, obesity, and oral diseases can lead to hospitalization, long-term disability, reduced quality of life, and death. In fact, persistent conditions are the nation’s leading cause of death and disability.
“Amongst POCT product type, blood glucose testing products dominated the market accounting for 75.1% share in 2018”
Based on POCT product, the report segments the market into, Blood Glucose Monitoring Test, Pregnancy & Fertility Testing, Infectious Disease Testing, Cardiac Markers, Anticoagulant Management, Others. Blood Glucose Monitoring Test products dominated the market and is expected to maintain its dominance throughout the forecast period 2019-2025. However, Infectious Disease Testing products are expected to witness the highest CAGR during the analyzed period.
“Over the Counter/Patient Self-Testing (OTC/PST) dominated the market in 2018”
Based on prescription type the global POCT market is segmented into Near the Patient (NPT) and Over the Counter (OTC) /Patient Self-Testing (PST). Over the Counter/Patient Self-Testing (OTC/PST) occupied the largest share and is expected to maintain its dominance throughout the forecast period 2019-2025. Lack of time among the individuals paired with increased disposable income and technological advancement would be the major driving factor for the growth of the segments
“Hospitals were the major end-user of POCT technology. The segment held 47.7% share in 2018”
On the basis of end-users, the report segments the global POCT market into Hospitals, Clinics & laboratories, home settings and others are the major end-users. In 2018, Hospitals were the largest revenue-generating segment for technology. However, increasing elderly population and associated diseases would drive the increased adoption of POCT for home setting, hence the segment is expected to witness highest CAGR growth of 6.09% during the forecast period 2019-2025.
“North America represents the largest markets for POCT technology globally in 2018, followed by Asia-Pacific and Europe”
For a deep-dive analysis of the overall adoption of POCT technology, detailed analysis was conducted for major regions/countries including North America (US, Canada), Europe (Germany, France, Spain, Italy, UK), Asia-Pacific (China, India, Japan, Australia) and Rest of the world. In 2018, North America dominated the market with ~half the market. However, increasing elderly populations majorly in countries such as Japan and China, Asia-Pacific would emerge as one of the larger markets for the technology in years to come.
Competitive Landscape-Top 10 Market Players
Roche Diagnostics, Becton, Dickinson and Company, Abbott Laboratories, Inc., Biomérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Johnson & Johnson, Siemens Healthineers, Sysmex Corporation and Thermo Fisher Scientific are some of the prominent players operating in the global point-of-care testing market at global scale. However, owing to increasing old age population and rising prevalence age-related disorders, the industry has witnessed emergence of numerous start-ups operating at regional/country level.
Reasons to buy:
• Current and future market size from 2018 to 2025 in terms of value (US$)
• Combined analysis of deep-dive secondary research and input from primary research through Key Opinion Leaders of the industry
• Country-level details of the overall adoption of point of care market along with value chain
• A quick review of overall industry performance at a glance
• In-depth analysis of key industry players
• A detailed analysis of regulatory framework, drivers, restraints, key trends and opportunities, value chain prevailing in the industry
• Examination of industry attractiveness with the help of Porter’s Five Forces analysis
• The study comprehensively covers the market across different segments and sub-segments of the technology
• Region/country Covered: North America (US, Canada and Rest of North America), Europe (UK, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, South Korea, Japan, Australia and Rest of Asia-Pacific), and Rest of the World
Customization Options:
The Global Point-of-Care testing Market can be customized to the country level or any other application. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients. The Global POCT Market can be customized to the country level or any other market segment.
1.1 Market Definition 20
1.2 Objective of the Study 20
1.3 Limitation 21
1.4 Stakeholders 21
1.5 Currency used in the Report 21
1.6 Scope of the Global Point-of-Care Testing Market Study 22
2. RESEARCH METHODOLOGY 23
2.1 Research Methodology for Global Point-of-Care Testing Market Study 23
2.1.1 Main objective of the Global Point-of-Care Testing Market Study 24
3. COMPREHENSIVE ASSESSMENT OF THE VALUE OF DIAGNOSTIC TESTS 25
3.1 General Overview 25
3.2 Capturing the full spectrum of the value that a diagnostic test contributes 29
3.3 Ensuring the Robust Analyses Underpin the Value Assessment 31
3.4 Accounting for variation in diagnostic test types in value assessment methods 32
3.5 Aligning on how to Define and Measure Value Drivered 34
3.5.1 Value Driver: Clinical Impact 34
3.5.2 Value Driver: Non-Clinical Patient Impact 36
3.5.3 Value Driver: Care Delivery Revenue and Cost Impact 37
3.5.4 Value Driver: Public/Population Impact 39
4. REFRAMING THE DIAGNOSTICS INDUSTRY 40
4.1 General Overview 40
5. COSTS AND BENEFITS OF DIAGNOSTIC TESTING 43
5.1 General Overview 43
5.2 Introduction and problem statement 43
5.2.1 Increasing healthcare costs 43
5.2.2 Underutilization of IVDs in clinical practice 43
5.3 Consequences for patient care 44
5.3.1 Conceptual interventions 45
5.3.1.1 Fostering prevention, screening, early diagnosis, and therapy 45
5.3.1.2 Promoting comprehensive disease management 46
5.3.1.3 Promoting Stratified Disease Management 47
5.3.1.4 Targeted delivery of treatment alongside companion diagnostics 48
5.4 Consequences for policies: promoting a fee for outcomes 50
5.5 Analysis of the Study 51
5.6 Conclusion 53
6. REGULATIONS & GUIDELINES OF POINT-OF-CARE TESTING 54
6.1 General Overview 54
6.2 The United States Point-Of-Care Testing Guidelines 55
6.2.1 Regulations 55
6.2.1.1 CLIA Waived Status for POCT 56
6.2.2 Guidelines 56
6.2.2.1 Obtain Authority to Coordinate Point-of-Care Testing Program 56
6.2.2.2 Select Members of Point-of-Care Committee (POCC) 56
6.2.2.3 Committee Develops a Point-of-Care-Program 57
6.2.2.4 Committee Reviews All Sites for Point-of-Care Testing 58
6.2.2.5 Evaluation of Proposed Testing 58
6.2.2.6 Implementation 60
6.2.2.7 Evaluation of Point-of-Care Testing Program 61
6.3 Canada Point-of-Care Testing Guidelines 61
6.4 Australia Point-of-Care Testing Guidelines 62
6.5 Dubai Point-of-Care Testing Guidelines by Health Regulation Department 63
6.5.1 Introduction 63
6.5.2 Professional Requirement 64
6.5.3 POCT Equipment 65
6.5.4 Documentation and Transmission of Results 66
6.5.5 Quality Control 66
7. RISK MITIGATION 67
7.1 General Overview 67
7.2 Supply Chain 68
7.3 Risk Assessment 69
7.4 Bulk, Custom and Contract Manufacturing 70
8. INDUSTRY PERFORMANCE 71
9. EXECUTIVE SUMMARY 72
10. MARKET OVERVIEW 74
10.1 Introduction of In-Vitro Diagnostics Market 74
10.1.1 Comparison of IVD & POCT 75
10.1.2 Main Categories of Diagnostics 77
10.1.3 Settings of Use 79
10.2 The key to accountable adoption of POCT 81
10.2.1 Drivers of diagnostic technology innovation and adoption: 82
10.2.2 Current challenges for diagnostic innovation 82
10.2.2.1 Regulation 82
10.2.2.2 Evidence generation 83
10.2.2.3 Clinical needs 83
10.2.2.4 Commissioning 83
10.2.2.5 Adoption 83
10.2.3 Current needs 83
10.2.3.1 Three key questions for diagnostic innovation: 83
10.2.4 Developing an evidence ‘toolkit’ for diagnostic test research 85
10.3 Value of Diagnostics to Health Care and Health Status 87
10.4 Current and Future Use of Diagnostic Products 88
10.4.1 Primary Uses of Diagnostics 88
10.4.1.1 Predictive Applications/Screening/Early Disease Detection 89
10.4.1.2 Diagnostics 89
10.4.1.3 Secondary Risk Assessment; Prognostic 89
10.4.1.4 Drug Selection/Treatment Targeting 89
10.4.1.5 Disease/Condition Monitoring and Management 90
10.4.2 In Vitro Diagnostics: Overview of Future Trends and Directions 90
10.4.2.1 Predict Disease Before Symptoms Appear 90
10.4.2.2 Predict Beneficial and Adverse Treatment Effects 91
10.4.2.3 Enable Personalized “Real-Time” Treatment and Disease Management Regimens 92
10.4.2.4 Facilitate Point-of-care and Near-patient Testing 93
10.4.2.5 Enable Home Testing 93
10.4.2.6 Public Health, Environmental, Bioterrorism Applications 94
10.4.2.7 Technology and Testing System Integration 95
10.4.3 The importance of Diagnostics in Healthcare 97
10.4.3.1 The role of diagnostics 97
10.4.3.2 Improving patient care 97
10.4.3.3 Reducing healthcare spending 98
10.4.3.4 Reasons In Vitro Diagnostics Are Superior 98
10.5 Market Dynamics 99
10.5.1 Market Drivers 99
10.5.1.1 Increasing Prevalence of Chronic Diseases 99
10.5.1.1.1 The Challenges of Chronic Disease 101
10.5.1.1.2 The Cost of Chronic Diseases 101
10.5.1.2 Rising Geriatric (Elderly) Population 103
10.5.1.3 Technology Advancement 104
10.5.2 Market Restraints 106
10.5.2.1 Stringent Government Regulations for the Manufacturing of POCT Products 106
10.5.2.2 Unfavourable Reimbursement Policies for POCT 107
10.5.2.3 Risk of errors 108
10.5.3 Market Opportunities 109
10.5.3.1 Development of Condition-Specific Markers and Tests 109
10.5.3.2 The growing significance of Companion Diagnostics 110
10.5.4 Market Trends 112
10.5.4.1 Changing Reimbursement Models and Regulations 112
10.5.4.2 Rising Investments in Unifying Technology 114
10.5.4.3 Consolidation and Automation of Labs 114
10.5.4.4 Shift towards Data-Driven Healthcare 115
11. KEY MARKET INDICATORS 116
11.1 Demand 116
11.2 Supply Side Analysis 118
11.2.1 Supply Chain Barriers 120
11.2.1.1 Product Launch 121
11.2.1.2 Partnership 126
11.2.1.3 Business Expansion & Investment 128
11.2.1.4 Mergers and Acquisitions 129
11.2.2 Value Chain Analysis of POC Testing 131
12. MARKET INSIGHT BY PRODUCT 132
12.1 General Overview 132
12.1.1 Blood Glucose Monitoring Test 133
12.1.2 Pregnancy & Fertility Testing 135
12.1.3 Infectious Disease Testing 136
12.1.4 Cardiac Markers 138
12.1.5 Anticoagulant Management 139
12.1.6 Others 140
13. MARKET INSIGHT BY PRESCRIPTION 142
13.1 General Overview 142
13.1.1 Near the Patient Testing (NPT) 143
13.1.2 Over the Counter (OCT) /Patient Self-Testing (PST) 144
14. MARKET INSIGHT BY END USER 145
14.1 General Overview 145
14.1.1 Hospitals 147
14.1.2 Clinics & Laboratory 149
14.1.3 Home Setting 152
14.1.4 Other Health Facilities 155
15. MARKET INSIGHT BY REGION 157
15.1 General Overview 157
15.2 North America POCT Market Insight 160
15.2.1 North America Point-of-Care Testing Market, By Product 161
15.2.2 North America Point-of-Care Testing Market by Prescription 161
15.2.3 North America Point-of-Care Testing Market by End-User 162
15.2.4 North America POCT Market by Country 162
15.2.4.1 United States 163
15.2.4.1.1 Key Findings on Healthcare Spending in the US, 2017 163
15.2.4.1.2 US Health Spending by Type of Service or Product, 2017 164
15.2.4.1.3 Health Spending by Major Sources of Funds 165
15.2.4.1.4 United States Point-of-Care Testing Market, By Product 166
15.2.4.1.5 United States Point-of-Care Testing Market by Prescription 166
15.2.4.1.6 United States Point-of-Care Testing Market by End-User 167
15.2.4.2 Canada 167
15.2.4.2.1 Key Findings on Canada Healthcare Spending, 2018 168
15.2.4.2.2 Key Findings on Hospital sector Spending in Canada, 2017 169
15.2.4.2.3 Canada Point-of-Care Testing Market, By Product 170
15.2.4.2.4 Canada Point-of-Care Testing Market by Prescription 171
15.2.4.2.5 Canada Point-of-Care Testing Market by End-User 171
15.2.4.3 Rest of North America 172
15.2.4.3.1 Rest of North America Point-of-Care Testing Market, By Product 173
15.2.4.3.2 Rest of North America Point-of-Care Testing Market by Prescription 174
15.2.4.3.3 Rest of North America Point-of-Care Testing Market by End-User 174
15.3 Europe POCT Market Insight 175
15.3.1 Europe Point-of-Care Testing Market, By Product 176
15.3.2 Europe Point-of-Care Testing Market by Prescription 176
15.3.3 Europe Point-of-Care Testing Market by End-User 177
15.3.4 Europe POCT Market by Country 177
15.3.4.1 Germany 178
15.3.4.1.1 Germany Point-of-Care Testing Market, By Product 179
15.3.4.1.2 Germany Point-of-Care Testing Market by Prescription 180
15.3.4.1.3 Germany Point-of-Care Testing Market by End-User 180
15.3.4.2 France 181
15.3.4.2.1 France Point-of-Care Testing Market, By Product 182
15.3.4.2.2 France Point-of-Care Testing Market by Prescription 182
15.3.4.2.3 France Point-of-Care Testing Market by End-User 183
15.3.4.3 Spain 183
15.3.4.3.1 Facts on Healthcare Sector Spain 184
15.3.4.3.2 Spain Point-of-Care Testing Market, By Product 185
15.3.4.3.3 Spain Point-of-Care Testing Market by Prescription 185
15.3.4.3.4 Spain Point-of-Care Testing Market by End-User 186
15.3.4.4 Italy 186
15.3.4.4.1 Italy Point-of-Care Testing Market, By Product 187
15.3.4.4.2 Italy Point-of-Care Testing Market by Prescription 188
15.3.4.4.3 Italy Point-of-Care Testing Market by End-User 188
15.3.4.5 United Kingdom 189
15.3.4.5.1 United Kingdom Point-of-Care Testing Market, By Product 191
15.3.4.5.2 United Kingdom Point-of-Care Testing Market by Prescription 191
15.3.4.5.3 United Kingdom Point-of-Care Testing Market by End-User 192
15.3.4.6 Rest of Europe 192
15.3.4.6.1 Rest of the Europe Point-of-Care Testing Market, By Product 194
15.3.4.6.2 Rest of the Europe Point-of-Care Testing Market by Prescription 194
15.3.4.6.3 Rest of the Europe Point-of-Care Testing Market by End-User 195
15.4 Asia-Pacific POCT Market Insight 195
15.4.1 Asia-Pacific Point-of-Care Testing Market, By Product 196
15.4.2 Asia-Pacific Point-of-Care Testing Market by Prescription 197
15.4.3 Asia-Pacific Point-of-Care Testing Market by End-User 197
15.4.4 Asia-Pacific POCT Market by Country 198
15.4.4.1 China 198
15.4.4.1.1 Facts on Chinese Elderly Population 199
15.4.4.1.2 China Point-of-Care Testing Market, By Product 200
15.4.4.1.3 China Point-of-Care Testing Market by Prescription 200
15.4.4.1.4 China Point-of-Care Testing Market by End-User 201
15.4.4.2 India 201
15.4.4.2.1 India Point-of-Care Testing Market, By Product 203
15.4.4.2.2 India Point-of-Care Testing Market by Prescription 203
15.4.4.2.3 India Point-of-Care Testing Market by End-User 204
15.4.4.3 Japan 204
15.4.4.3.1 Japan Point-of-Care Testing Market, By Product 206
15.4.4.3.2 Japan Point-of-Care Testing Market by Prescription 207
15.4.4.3.3 Japan Point-of-Care Testing Market by End-User 207
15.4.4.4 Australia 208
15.4.4.4.1 Australia Point-of-Care Testing Market, By Product 210
15.4.4.4.2 Australia Point-of-Care Testing Market by Prescription 210
15.4.4.4.3 Australia Point-of-Care Testing Market by End-User 211
15.4.4.5 Rest of Asia-Pacific 211
15.4.4.5.1 Health Expenditure 212
15.4.4.5.2 Public Hospital Funding - District Health Boards 212
15.4.4.5.3 Mental Health 212
15.4.4.5.4 Disability Support Services 212
15.4.4.5.5 Reduction in costs of visiting GP 212
15.4.4.5.6 Rest of APAC Point-of-Care Testing Market, By Product 213
15.4.4.5.7 Rest of APAC Point-of-Care Testing Market by Prescription 214
15.4.4.5.8 Rest of APAC Point-of-Care Testing Market by End-User 214
15.5 Rest of World Market Insight 215
15.5.1 Rest of World Point-of-Care Testing Market, By Product 217
15.5.2 Rest of the world Point-of-Care Testing Market by Prescription 217
15.5.3 Rest of the world Point-of-Care Testing Market by End-User 218
16. COMPETITIVE SCENARIO 219
16.1 Porter’s Five forces analysis 219
16.1.1 Bargaining Power of Suppliers 220
16.1.2 Bargaining Power of Buyers 220
16.1.3 Threat of New Entrants 221
16.1.4 Threat of Substitutes 222
16.1.5 Industry Rivalry 222
16.2 Market Share Analysis, by Company 223
16.2.1 Global Point-of-Care Testing Market Share Analysis, by Company 2018 223
17. TOP COMPANY PROFILES 225
17.1 Abbott Laboratories 225
17.1.1 Key Facts 225
17.1.2 Business Description 225
17.1.3 Key Product/Services Offerings 226
17.1.4 Growth Strategy 226
17.1.5 SWOT Analysis 227
17.1.6 Key Financials 228
17.1.6.1 Revenue Split 229
17.1.7 Recent Developments 229
17.1.7.1 Product Launches 229
17.1.7.2 Partnership 231
17.1.7.3 Merger and Acquisition 232
17.2 Becton, Dickinson and Company 233
17.2.1 Key Facts 233
17.2.2 Business Description 233
17.2.3 Becton Dickinson, and Company, Key Product/Services Offerings 233
17.2.4 Growth Strategy 234
17.2.5 SWOT Analysis 235
17.2.6 Key Financials 236
17.2.6.1 Revenue Split 237
17.2.7 Recent Developments 237
17.2.7.1 Product Launches 237
17.2.7.2 Business Expansions and Investments 238
17.2.7.3 Merger & Acquisition 238
17.3 Biomérieux SA 239
17.3.1 Key Facts 239
17.3.2 Business Description 239
17.3.3 Key Product/Services Offerings 240
17.3.4 Growth Strategy 240
17.3.5 SWOT Analysis 241
17.3.6 Key Financials 242
17.3.6.1 Revenue Split 243
17.3.7 Recent Developments 243
17.3.7.1 Product Launches 243
17.3.7.2 Partnerships 244
17.3.7.3 Mergers and Acquisitions 244
17.4 Bio-Rad Laboratories, Inc. 246
17.4.1 Key Facts 246
17.4.2 Business Description 246
17.4.3 Key Product/Services Offerings 247
17.4.4 Growth Strategy 248
17.4.5 SWOT Analysis 249
17.4.6 Key Financials 250
17.4.6.1 Revenue Split 251
17.4.7 Recent Developments 251
17.4.7.1 Product Launches 251
17.4.7.2 Mergers and Acquisition 252
17.5 Danaher Corporation 253
17.5.1 Key Facts 253
17.5.2 Business Description 253
17.5.3 Key Product/Services Offerings 253
17.5.4 Growth Strategy 254
17.5.5 SWOT Analysis 255
17.5.6 Key Financials 256
17.5.6.1 Revenue Split 257
17.5.7 Recent Developments 257
17.5.7.1 Merger and Acquisitions 257
17.6 Johnson & Johnson 258
17.6.1 Key Facts 258
17.6.2 Business Description 258
17.6.3 Key Product/Services Offerings 259
17.6.4 Growth Strategy 259
17.6.5 SWOT Analysis 260
17.6.6 Key Financials 261
17.6.6.1 Revenue Split 262
17.7 Roche Holding AG 263
17.7.1 Key Facts 263
17.7.2 Business Description 263
17.7.3 Key Product/Services Offerings 264
17.7.4 Growth Strategy 264
17.7.5 SWOT Analysis 265
17.7.6 Key Financials 266
17.7.6.1 Revenue Split 267
17.7.7 Recent Developments 267
17.7.7.1 Product Launches 267
17.7.7.2 Partnership 268
17.7.7.3 Mergers and Acquisitions 269
17.8 Siemens Healthineers AG 270
17.8.1 Key Facts 270
17.8.2 Business Description 270
17.8.3 Key Product/Services Offerings 271
17.8.4 Growth Strategy 271
17.8.5 SWOT Analysis 272
17.8.6 Key Financials 273
17.8.6.1 Revenue Split 274
17.8.7 Recent Developments 274
17.8.7.1 Product Launches 274
17.8.7.2 Partnerships 275
17.8.7.3 Business Expansion and Investment 275
17.8.7.4 Merger and Acquisition 275
17.9 Thermo Fisher Scientific 277
17.9.1 Key Facts 277
17.9.2 Business Description 277
17.9.3 Key Product/Services Offerings 278
17.9.4 Growth Strategy 280
17.9.5 SWOT Analysis 280
17.9.6 Key Financials 281
17.9.6.1 Revenue Split 282
17.9.7 Recent Developments 282
17.9.7.1 Product Launches 282
17.9.7.2 Partnerships 283
17.9.7.3 Business Expansion and Investments 283
17.9.7.4 Merger and Acquisition 284
17.10 Sysmex Corporation 285
17.10.1 Key Facts 285
17.10.2 Business Description 285
17.10.3 Key Product/Services Offerings 285
17.10.4 Growth Strategy 286
17.10.5 SWOT Analysis 287
17.10.6 Key Financials 288
17.10.6.1 Revenue Split 289
17.10.7 Recent Developments 289
17.10.7.1 Product Launches 289
17.10.7.2 Partnership 290
17.10.7.3 Business Expansion & Investments 291
17.10.7.4 Merger and Acquisition 291
TABLE 2 Considerations in Demonstrating Value by Diagnostic Test Type 33
TABLE 3 Value Driver: Clinical Impact 34
TABLE 4 Value Driver: Non-Clinical Patient Impact 36
TABLE 5 Value Driver: Care Delivery Revenue and Cost Impact 37
TABLE 6 Value Driver: Public/Population Impact 39
TABLE 7 Overview of Selected Compounds and their Companion Diagnostics, beyond the field of Oncology 49
TABLE 8 Application of the outcome measures hierarchical tier system described by Porter to reinforcement interventions proposed as solutions to the shifting the burden archetype in the in-vitro diagnostics arena 50
TABLE 9 The risk Identified by POCT Manufacturers and Solutions 67
TABLE 10 Examples of Commonly Used POCT 75
TABLE 11 Categories and Examples of Diagnostic Products 78
TABLE 12 Rapidly Expanding Areas of Scientific Inquiry 91
TABLE 13 Number and distribution of persons aged 60 years or over by region, in 2017 and 2050 104
TABLE 14 Classification system for IVD’s medical devices based on risk 107
TABLE 15 Oncology CDx Market: Selected Tests Resulting from Partnerships, U.S., 2017 112
TABLE 16 POCT Market Regulatory Analysis, Selected Regions 113
TABLE 17 Recent Product Launches 121
TABLE 18 Recent Partnership 126
TABLE 19 Recent Expansion Expansions & Investment 128
TABLE 20 Mergers and Acquisitions 129
TABLE 21 Global Point-of-Care Testing Market, By Product, 2018-2025 (US$ Million) 133
TABLE 22 Clinical Laboratory Improvement Amendments (CLIA)-waived tests for Infectious Diseases 137
TABLE 23 Percentage of time in the target range 144
TABLE 24 General POCT for Primary Health Care 151
TABLE 25 Countries with Shift in Average Life Expectancies in 2030 157
TABLE 26 Ten countries with the largest share of persons aged 60 years 2017 & 2025 158
TABLE 27 North America Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 161
TABLE 28 United States Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 166
TABLE 29 Canada Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 170
TABLE 30 Rest of North America Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 173
TABLE 31 Europe Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 176
TABLE 32 Germany Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 179
TABLE 33 France Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 182
TABLE 34 Spain Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 185
TABLE 35 Italy Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 187
TABLE 36 United Kingdom Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 191
TABLE 37 Rest of the Europe Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 194
TABLE 38 Asia-Pacific Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 196
TABLE 39 China Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 200
TABLE 40 India Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 203
TABLE 41 Japan Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 206
TABLE 42 Australia, Total Health Expenses, US$ Million 210
TABLE 43 Australia Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 210
TABLE 44 Rest of APAC Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 213
TABLE 45 Rest of World Point-of-Care Testing Market by Product, 2018-2025 (US$ Million) 217
TABLE 46 Abbott Laboratories Key Facts 225
TABLE 47 Product segmentation of Abbott Laboratories 226
TABLE 48 Abbott Laboratories Growth Strategy 226
TABLE 49 Abbott Laboratories, Inc. Product Launches 229
TABLE 50 Abbott Laboratories, Inc. Partnership 231
TABLE 51 Abbott Laboratories, Inc. Merger and Acquisition 232
TABLE 52 Becton, Dickinson and Company Key Facts 233
TABLE 53 Becton, Dickinson and Company Key Product/ Services Offerings 233
TABLE 54 Becton, Dickinson and Company Growth Strategy 234
TABLE 55 Becton, Dickinson and Company Product Launches 237
TABLE 56 Becton, Dickinson and Company Business Expansions and Investments 238
TABLE 57 Becton, Dickinson and Company Merger & Acquisition 238
TABLE 58 Biomérieux SA Key Facts 239
TABLE 59 Product segmentation of Biomérieux SA 240
TABLE 60 Biomérieux SA Growth Strategy 240
TABLE 61 Biomérieux SA Product Launches 243
TABLE 62 Biomérieux SA Partnerships 244
TABLE 63 Biomérieux SA Mergers and Acquisitions 244
TABLE 64 Bio-Rad Laboratories, Inc. Key Facts 246
TABLE 65 Product Segmentation of Bio-Rad Laboratories, Inc. 247
TABLE 66 Bio-Rad Laboratories, Inc. Growth Strategy 248
TABLE 67 Bio-Rad Laboratories, Inc. Product Launches 251
TABLE 68 Bio-Rad Laboratories, Inc. Merger and Acquisition 252
TABLE 69 Danaher Corporation Key Facts 253
TABLE 70 Product Segmentation of Danaher Corporation 253
TABLE 71 Danaher Corporation Growth Strategy 254
TABLE 72 Danaher Corporation Merger and Acquisitions 257
TABLE 73 Johnson & Johnson Key Facts 258
TABLE 74 Product segmentation of Johnson & Johnson 259
TABLE 75 Johnson & Johnson Growth Strategy 259
TABLE 76 Roche Holding AG Key Facts 263
TABLE 77 Product Segmentation of Roche Holding AG 264
TABLE 78 Roche Holding AG Growth Strategy 264
TABLE 79 Roche Holding AG Product Launches 267
TABLE 80 Roche Holding AG Partnership 268
TABLE 81 Roche Holding AG Mergers and Acquisitions 269
TABLE 82 Siemens Healthineers AG Key Facts 270
TABLE 83 Product Segmentation of Siemens Healthineers AG 271
TABLE 84 Siemens Healthineers AG Growth Strategy 271
TABLE 85 Siemens Healthineers AG Product Launches 274
TABLE 86 Siemens Healthineers AG Partnerships 275
TABLE 87 Siemens Healthineers Business Expansion and Investment 275
TABLE 88 Siemens Healthineers Merger and Acquisition 275
TABLE 89 Thermo Fisher Scientific Key Facts 277
TABLE 90 Product segmentation of Thermo Fisher Scientific 278
TABLE 91 Thermo Fisher Scientific Growth Strategy 280
TABLE 92 Thermo Fisher Scientific Product Launches 282
TABLE 93 Thermo Fisher Scientific Partnerships 283
TABLE 94 Thermo Fisher Scientific Business Expansion and Investments 283
TABLE 95 Thermo Fisher Scientific Merger and Acquisition 284
TABLE 96 Sysmex Corporation Key Facts 285
TABLE 97 Product segmentation of Sysmex Corporation 285
TABLE 98 Sysmex Corporation Growth Strategy 286
TABLE 99 Sysmex Corporation Product Launches 289
TABLE 100 Sysmex Corporation Partnership 290
TABLE 101 Sysmex Corporation Business Expansion & Investments 291
TABLE 102 Sysmex Corporation Merger and Acquisition 291
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
